Biotech Values

[pcrutch]

Some interesting data coming out of ESMO in regards to Alpharadin

Alpharadin Phase III Trial Data to be presented at Best and Late-Breaking Session at the 2011 European Multidisciplinary Cancer Congress

Algeta ASA (OSE: ALGETA) announces that results from its phase III ALSYMPCA clinical study evaluating Alpharadin (radium-223) for treating patients with symptomatic bone metastases from castration-resistant prostate cancer (CRPC) will be presented at the Presidential Session I: Best and Late-Breaking Abstracts at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden (23-27 September 2011). The results will cover the primary and secondary efficacy endpoints as well as safety data from the ALSYMPCA phase III clinical study.

In June 2011, Algeta and Bayer Pharma AG (Bayer) announced that the phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial met its primary endpoint by significantly improving overall survival. The trial was stopped early based on this positive result and a recommendation from the Independent Data Monitoring Committee (IDMC), following a pre-planned interim analysis.

Details of the presentation are as follows:

Presentation title: Overall Survival Benefit of Radium-223 Chloride (Alpharadin(TM)) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Presenter: Dr. Christopher Parker (Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK)

PRESIDENTIAL SESSION I: BEST AND LATE-BREAKING ABSTRACTS (1LBA)
Saturday 24 September, 14.35-14.45 (CEST)
Hall A1

In addition, there will be a poster session providing further 24-month phase II safety data from the Alpharadin clinical program. Details of this poster are as follows:

Poster title: Twenty-four-month Safety Data From Phase II Studies of Radium-223 Chloride, a First-in-class Alpha-pharmaceutical With a Highly Favorable Safety Profile for Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases

Presenter: Dr. Sten Nilsson (Karolinska Institute, Stockholm, Sweden)

Abstract #7008, Poster Session Genitourinary Malignancies - Prostate Cancer
Sunday 25 September, 14.00-16.30 (CEST)
Hall A8